Beneficient Reports Results for Fourth Quarter & Fiscal Year Ended March 31, 2025

Transformative Year Reduced Operating Costs, Launched New Products and Improved Financial Position Beneficient is Positioned to Capitalize on ...
Santé log

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia

Following the 2 most recent cases of anaphylaxis, Larimar consulted its experts and decided to modify its starting dose regimen; Larimar provided the FDA a full update on the clinical development ...